Weekly Analysts’ Ratings Changes for Vir Biotechnology (VIR)

Several analysts have recently updated their ratings and price targets for Vir Biotechnology (NASDAQ: VIR):

• 3/4/2026 – Vir Biotechnology had its price target raised by HC Wainwright from $15.00 to $20.00. They now have a “buy” rating on the stock.
• 2/28/2026 – Vir Biotechnology was upgraded by Wall Street Zen from “sell” to “hold”.
• 2/26/2026 – Vir Biotechnology had its “outperform” rating reaffirmed by Leerink Partners. They now have a $20.00 price target on the stock.
• 2/24/2026 – Vir Biotechnology had its price target raised by Barclays PLC from $26.00 to $30.00. They now have an “overweight” rating on the stock.
• 2/24/2026 – Vir Biotechnology had its “outperform” rating reaffirmed by Evercore Inc. They now have a $18.00 price target on the stock.
• 2/24/2026 – Vir Biotechnology had its price target raised by Morgan Stanley from $20.00 to $24.00. They now have an “overweight” rating on the stock.
• 2/24/2026 – Vir Biotechnology was upgraded by Raymond James Financial, Inc. from “outperform” to “strong-buy”. They now have a $19.00 price target on the stock.
• 2/24/2026 – Vir Biotechnology had its price target raised by Needham & Company LLC from $14.00 to $18.00. They now have a “buy” rating on the stock.
• 2/17/2026 – Vir Biotechnology was given a new $26.00 price target by Barclays PLC.
• 2/9/2026 – Vir Biotechnology had its “buy” rating reaffirmed by Needham & Company LLC. They now have a $14.00 price target on the stock.
• 2/4/2026 – Vir Biotechnology had its “overweight” rating reaffirmed by Barclays PLC. They now have a $24.00 price target on the stock.

Insider Buying and Selling at Vir Biotechnology

In other news, Director Vicki L. Sato sold 42,377 shares of the business’s stock in a transaction that occurred on Tuesday, February 24th. The stock was sold at an average price of $9.75, for a total value of $413,175.75. Following the completion of the sale, the director directly owned 1,144,391 shares in the company, valued at $11,157,812.25. The trade was a 3.57% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, EVP Verneuil Vanina De sold 13,700 shares of the stock in a transaction that occurred on Wednesday, February 25th. The shares were sold at an average price of $9.82, for a total value of $134,534.00. Following the transaction, the executive vice president owned 112,982 shares in the company, valued at $1,109,483.24. This trade represents a 10.81% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders sold 177,546 shares of company stock worth $1,522,174. Insiders own 16.00% of the company’s stock.

Vir Biotechnology, Inc is a clinical?stage immunology company dedicated to developing therapies that prevent and treat serious infectious diseases. The company leverages a suite of proprietary technology platforms—ranging from antibody isolation and screening tools to cell?based assays and bioinformatics—to identify and advance antiviral and antibacterial candidates. Its scientific approach centers on harnessing the human immune system through monoclonal antibodies and immunomodulatory agents.

The company’s pipeline includes product candidates targeting influenza A, COVID?19, HIV, hepatitis B, and tuberculosis.